Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand
Elutia, Inc. - Class A (ELUT)
Company Research
Source: GlobeNewswire
First FDA-Cleared Antibiotic-Eluting BioEnvelope Now Available in U.S. for Implantable Pacemakers, Defibrillators, and Neurostimulators SILVER SPRING, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix technologies, announced the U.S. commercial launch of EluPro™, the first and only FDA-cleared antibiotic-eluting biomatrix designed for use with cardiac implantable electronic devices (CIEDs) and neurostimulators. “EluPro is an exciting innovation that addresses two critical challenges for patients with implantable devices: preventing infection and promoting healthy healing of the surgical pocket,” said Sunil Kapur, M.D., Cardiac Electrophysiologist at Brigham and Women’s Hospital. “The unique combination of powerful antibiotic protection and natural biomatrix technology represents a significant step forward in improving outcomes for patients. I am eager to see this technology benefit the field of electrophysiology.” This full
Show less
Read more
Impact Snapshot
Event Time:
ELUT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELUT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELUT alerts
High impacting Elutia, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ELUT
News
- Elutia (NASDAQ:ELUT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ELUT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to MarketBeat
- Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x DevelopmentGlobeNewswire
- Elutia (NASDAQ:ELUT) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025GlobeNewswire
- Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21GlobeNewswire
ELUT
Sec Filings
- 12/15/25 - Form 4
- 12/15/25 - Form SCHEDULE
- 12/12/25 - Form 4
- ELUT's page on the SEC website